You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
Baxter
Medtronic
McKesson
Moodys

Last Updated: June 2, 2020

DrugPatentWatch Database Preview

Eyevance Company Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Summary for Eyevance
International Patents:15
US Patents:7
Tradenames:6
Ingredients:6
NDAs:6

Drugs and US Patents for Eyevance

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eyevance TOBRADEX ST dexamethasone; tobramycin SUSPENSION/DROPS;OPHTHALMIC 050818-001 Feb 13, 2009 RX Yes Yes 8,450,287   Start Trial Y   Start Trial
Eyevance TOBRASONE fluorometholone acetate; tobramycin SUSPENSION/DROPS;OPHTHALMIC 050628-001 Jul 21, 1989 DISCN No No   Start Trial   Start Trial
Eyevance ZERVIATE cetirizine hydrochloride SOLUTION/DROPS;OPHTHALMIC 208694-001 May 30, 2017 RX Yes Yes 9,254,286*PED   Start Trial Y   Start Trial
Eyevance VEXOL rimexolone SUSPENSION/DROPS;OPHTHALMIC 020474-001 Dec 30, 1994 DISCN No No   Start Trial   Start Trial
Eyevance FLAREX fluorometholone acetate SUSPENSION/DROPS;OPHTHALMIC 019079-001 Feb 11, 1986 RX Yes Yes   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Eyevance

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Eyevance TOBRADEX ST dexamethasone; tobramycin SUSPENSION/DROPS;OPHTHALMIC 050818-001 Feb 13, 2009 5,149,694   Start Trial
Eyevance VEXOL rimexolone SUSPENSION/DROPS;OPHTHALMIC 020474-001 Dec 30, 1994 4,686,214   Start Trial
Eyevance TOBRASONE fluorometholone acetate; tobramycin SUSPENSION/DROPS;OPHTHALMIC 050628-001 Jul 21, 1989 5,149,693   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for Eyevance Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1429780 SPC/GB12/058 United Kingdom   Start Trial PRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003
0058146 2001C/045 Belgium   Start Trial PRODUCT NAME: DICHLORHYDRATE DE LEVOCETIRIZINE; NAT RER. NO/DATE: 194 IS 90 F3 20011022; FIRST REG.: DE 49903.00.00 20010103
1429780 13C0012 France   Start Trial PRODUCT NAME: COMBINAISON DE CIPROFLOXACINE ET DE DEXAMETHASONE, EN PARTICULIER DE CHLORHYDRATE DE CIPROFLOXACINE ET DE DEXAMETHASONE; NAT. REGISTRATION NO/DATE: NL 41308 20121214; FIRST REGISTRATION: 48976 20120808
1581193 SPC/GB12/047 United Kingdom   Start Trial PRODUCT NAME: DEXAMETHASONE; REGISTERED: UK EU/1/10/638/001 20100727
0663828 C300085 Netherlands   Start Trial PRODUCT NAME: LEVOCETIRIZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER LEVOCETIRINE DIHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 26770 20011009; FIRST REGISTRATION: DE 49903.00.00 AND 49904.00.00 20010103
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
Merck
Boehringer Ingelheim
McKinsey
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.